About Grifols, S.A. (NASDAQ:GRFS)
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Industry, Sector and Symbol:
- Industry: Biotechnology
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:GRFS
- CUSIP: N/A
- Web: www.grifols.com
- Debt-to-Equity Ratio: 1.69%
- Current Ratio: 3.17%
- Quick Ratio: 1.39%
Sales & Book Value:
- Trailing P/E Ratio: 21.56
- Forward P/E Ratio: 19.97
- P/E Growth: 1.7
- Annual Sales: $4.48 billion
- Price / Sales: 3.53
- Cash Flow: $1.33 per share
- Price / Cash: 17.41
- Book Value: $6.04 per share
- Price / Book: 3.84
- Annual Dividend: $0.28
- Dividend Yield: 1.2%
- Net Income: $603.60 million
- Net Margins: 13.16%
- Return on Equity: 18.08%
- Return on Assets: 6.22%
- Employees: 14,877
- Outstanding Shares: 682,820,000
Frequently Asked Questions for Grifols, S.A. (NASDAQ:GRFS)
What is Grifols, S.A.'s stock symbol?
Grifols, S.A. trades on the NASDAQ under the ticker symbol "GRFS."
How often does Grifols, S.A. pay dividends? What is the dividend yield for Grifols, S.A.?
Grifols, S.A. declared a semiannual dividend on Friday, May 26th. Stockholders of record on Thursday, June 1st will be given a dividend of $0.122 per share on Thursday, June 8th. This represents a dividend yield of 1.54%. The ex-dividend date is Tuesday, May 30th. View Grifols, S.A.'s Dividend History.
When did Grifols, S.A.'s stock split? How did Grifols, S.A.'s stock split work?
Grifols, S.A. shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were issued to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols, S.A. stock prior to the split would have 200 shares after the split.
Who are some of Grifols, S.A.'s key competitors?
Some companies that are related to Grifols, S.A. include Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Sirtex Medical Limited (SRX), Theratechnologies (TH), Mirati Therapeutics (MRTX), OrganiGram Holdings (OGI), Siga Technologies (SIGA), VBI Vaccines (VBIV), XOMA Corporation (XOMA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), ContraFect Corporation (CFRX), Concordia International Corp. (CXR), Soligenix (SNGX), Senesco Technologies (SVON) and Mateon Therapeutics (MATN).
Who owns Grifols, S.A. stock?
Grifols, S.A.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Harding Loevner LP (13.12%), AKO Capital LLP (1.68%), Artisan Partners Limited Partnership (1.55%), Bank of New York Mellon Corp (0.91%), Pictet Asset Management Ltd. (0.32%) and Vaughan Nelson Investment Management L.P. (0.21%). View Institutional Ownership Trends for Grifols, S.A..
Who sold Grifols, S.A. stock? Who is selling Grifols, S.A. stock?
Grifols, S.A.'s stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Pictet Asset Management Ltd., AKO Capital LLP, Gladstone Capital Management LLP, Rock Point Advisors LLC, Oppenheimer Asset Management Inc., Beck Mack & Oliver LLC and Santa Barbara Asset Management LLC. View Insider Buying and Selling for Grifols, S.A..
Who bought Grifols, S.A. stock? Who is buying Grifols, S.A. stock?
Grifols, S.A.'s stock was purchased by a variety of institutional investors in the last quarter, including Harding Loevner LP, Westpac Banking Corp, GABELLI & Co INVESTMENT ADVISERS INC., First Trust Advisors LP, Citadel Advisors LLC, Gabelli Funds LLC, Ameriprise Financial Inc. and Van ECK Associates Corp. View Insider Buying and Selling for Grifols, S.A..
How do I buy Grifols, S.A. stock?
Shares of Grifols, S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Grifols, S.A.'s stock price today?
One share of Grifols, S.A. stock can currently be purchased for approximately $23.17.
How big of a company is Grifols, S.A.?
Grifols, S.A. has a market capitalization of $6.09 billion and generates $4.48 billion in revenue each year. Grifols, S.A. employs 14,877 workers across the globe.
How can I contact Grifols, S.A.?
Grifols, S.A.'s mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]
MarketBeat Community Rating for Grifols, S.A. (NASDAQ GRFS)MarketBeat's community ratings are surveys of what our community members think about Grifols, S.A. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Grifols, S.A. (NASDAQ:GRFS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Grifols, S.A. (NASDAQ:GRFS)
Analysts' Ratings History for Grifols, S.A. (NASDAQ:GRFS)
(Data available from 11/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/31/2017||Citigroup Inc.||Initiated Coverage||Buy -> Buy||N/A|
|7/4/2017||Bank of America Corporation||Reiterated Rating||Buy||Medium|
|6/30/2017||Goldman Sachs Group, Inc. (The)||Downgrade||Buy -> Neutral||Low|
|3/30/2017||J P Morgan Chase & Co||Upgrade||Neutral -> Overweight||High|
|6/6/2016||Morgan Stanley||Reiterated Rating||Sell||N/A|
|2/9/2016||Berenberg Bank||Upgrade||Hold -> Buy||N/A|
Earnings History for Grifols, S.A. (NASDAQ:GRFS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Grifols, S.A. (NASDAQ:GRFS)
2017 EPS Consensus Estimate: $1.13
2018 EPS Consensus Estimate: $1.27
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Grifols, S.A. (NASDAQ:GRFS)
|Most Recent Dividend:||6/8/2017|
|Payout Ratio:||24.14% (Based on This Year's Estimates)|
21.54% (Based on Next Year's Estimates)
Dividend History by Quarter for Grifols, S.A. (NASDAQ GRFS)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Grifols, S.A. (NASDAQ GRFS)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Grifols, S.A. (NASDAQ GRFS)
|Grifols, S.A. (GRFS) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - November 21 at 3:52 AM
|ETFs with exposure to Grifols SA : November 16, 2017|
finance.yahoo.com - November 16 at 2:52 PM
|$0.29 Earnings Per Share Expected for Grifols, S.A. (GRFS) This Quarter|
www.americanbankingnews.com - November 7 at 5:40 PM
|William Blair Analysts Reduce Earnings Estimates for Grifols, S.A. (GRFS)|
www.americanbankingnews.com - November 6 at 5:24 AM
|Visit To Grifols' Headquarters During Tumultuous Time In Catalonia - Seeking Alpha|
seekingalpha.com - November 3 at 9:09 PM
|ETFs with exposure to Grifols SA : November 2, 2017|
finance.yahoo.com - November 2 at 10:32 PM
|Stocks Showing Rising Market Leadership: Grifols Earns 83 RS Rating|
finance.yahoo.com - October 31 at 8:39 PM
|Grifols, S.A. (GRFS) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - October 27 at 3:28 AM
|Grifols, (GRFS) vs. ContraFect Corporation (CFRX) Head to Head Comparison|
www.americanbankingnews.com - October 24 at 2:14 PM
|ETFs with exposure to Grifols SA : October 23, 2017|
finance.yahoo.com - October 23 at 6:55 PM
|Cubist Pharmaceuticals (CBST) & Grifols, (GRFS) Critical Review|
www.americanbankingnews.com - October 22 at 6:22 AM
|ContraFect Corporation (CFRX) & Grifols, (GRFS) Head to Head Contrast|
www.americanbankingnews.com - October 19 at 9:07 AM
|ETFs with exposure to Grifols SA : October 10, 2017|
finance.yahoo.com - October 10 at 4:53 PM
|Grifols SA :GRFS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017|
finance.yahoo.com - October 9 at 7:22 PM
|Grifols, (GRFS) versus Its Peers Financial Review|
www.americanbankingnews.com - October 9 at 4:12 PM
|FACTBOX-Companies with big business operations in Catalonia|
www.cnbc.com - October 7 at 6:03 AM
|Grifols, S.A. (GRFS) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - October 2 at 12:44 AM
|Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Cylinder)?|
seekingalpha.com - September 29 at 4:34 PM
|Grifols, (GRFS) vs. Its Peers Head-To-Head Analysis|
www.americanbankingnews.com - September 28 at 6:16 PM
|Grifols, (GRFS) versus Its Rivals Critical Comparison|
www.americanbankingnews.com - September 27 at 2:06 AM
|Cubist Pharmaceuticals (CBST) and Grifols, (GRFS) Critical Contrast|
www.americanbankingnews.com - September 25 at 6:32 AM
|Head to Head Survey: Idenix Pharmaceuticals (IDIX) & Grifols, (GRFS)|
www.americanbankingnews.com - September 23 at 12:40 PM
|Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The Chamber)?|
seekingalpha.com - September 22 at 6:51 PM
|Should Value Investors Consider Grifols (GRFS) Stock Now? - Nasdaq|
www.nasdaq.com - September 22 at 1:50 PM
|Financial Comparison: Grifols, (GRFS) versus The Competition|
www.americanbankingnews.com - September 22 at 2:20 AM
|Should Value Investors Consider Grifols (GRFS) Stock Now?|
finance.yahoo.com - September 20 at 4:18 PM
|Head-To-Head Contrast: Grifols, (GRFS) & Its Peers|
www.americanbankingnews.com - September 16 at 8:24 PM
|Financial Survey: Grifols, (GRFS) and Dendreon (DNDN)|
www.americanbankingnews.com - September 15 at 10:21 AM
|3 Pharma/Biotech Sector Bargains for a Healthy Portfolio|
finance.yahoo.com - September 14 at 3:13 AM
|Grifols, S.A. (GRFS) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - September 7 at 12:30 AM
|Comparing Humanigen (KBIO) & Grifols, (GRFS)|
www.americanbankingnews.com - September 5 at 8:46 PM
|Technical Insights on Biotech Stocks -- Grifols, Halozyme Therapeutics, Illumina, and VIVUS - PR Newswire (press release)|
www.prnewswire.com - September 1 at 7:36 PM
|Grifols Is a Leader in High-Demand Plasma|
finance.yahoo.com - August 29 at 7:45 PM
|Stocks Flashing Renewed Technical Strength: Grifols|
finance.yahoo.com - August 28 at 11:54 PM
|Head to Head Contrast: Onyx Pharmaceuticals (ONXX) & Grifols SA, Barcelona (GRFS)|
www.americanbankingnews.com - August 18 at 12:22 AM
|Analyzing Durata Therapeutics (DRTX) and Grifols, (GRFS)|
www.americanbankingnews.com - August 17 at 8:48 AM
|XOMA Corporation (XOMA) vs. Grifols, (NASDAQ:GRFS) Head-To-Head Comparison|
www.americanbankingnews.com - August 13 at 12:10 AM
|Trio of companies redraws map of East Bay drug manufacturing|
www.bizjournals.com - August 3 at 4:06 PM
|Select American Red Cross Blood Donations Screened for Babesia Parasite Using Grifols' Procleix Babesia Assay Under an Investigational New Drug Protocol|
finance.yahoo.com - August 1 at 7:45 PM
|3 Things In Biotech You Should Learn Today: July 31, 2017|
seekingalpha.com - July 31 at 6:48 PM
|European ADRs Move Lower in Friday Trading - Nasdaq|
www.nasdaq.com - July 28 at 9:52 PM
|Grifols, S.A. (NASDAQ:GRFS) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - July 19 at 12:16 AM
|Interesting GRFS Put And Call Options For February 2018 - Nasdaq ... - Nasdaq|
www.nasdaq.com - June 21 at 7:11 PM
|Should Value Investors Consider Grifols (GRFS) Stock Right Now? - Nasdaq|
www.nasdaq.com - June 16 at 6:16 PM
|Should You Get Rid of USANA Health Sciences (USNA) Now?|
www.zacks.com - March 6 at 8:58 AM
|Interesting GRFS Put And Call Options For August 2017 - Nasdaq|
www.nasdaq.com - December 21 at 6:24 PM
|Interesting GRFS Put And Call Options For August 2017|
www.nasdaq.com - December 20 at 10:28 PM
|Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B|
www.thestreet.com - December 14 at 11:15 PM
|Hologic to sell stake in blood screening unit for $1.85 bln|
www.marketwatch.com - December 14 at 6:13 PM
|Bullish Two Hundred Day Moving Average Cross - GRFS|
www.nasdaq.com - November 10 at 11:01 PM
Financials are not available for this stock.
Grifols, S.A. (NASDAQ GRFS) Chart for Tuesday, November, 21, 2017